Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.

被引：0

作者：

Kaseb, Ahmed Omar ^{[1
]}

Pestana, Roberto Carmagnani ^{[1
]}

Vence, Luis M. ^{[1
]}

Blando, Jorge M. ^{[1
]}

Singh, Shalini ^{[1
]}

Ikoma, Naruhiko ^{[1
]}

Vauthey, Jean-Nicolas ^{[1
]}

Allison, James Patrick ^{[1
]}

Sharma, Padmanee ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期

关键词：

D O I：

10.1200/JCO.2019.37.8_suppl.52

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[1] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Vauthey, Jean-Nicolas
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[2] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Raghav, Kanwal Pratap Singh
Sakamuri, Divya
Girard, Lauren
Tan, Dongfeng
Vauthey, Jean-Nicolas
Tzeng, Ching-Wei David
Aloia, Thomas A.
Chun, Yun Shin
Yao, James C.
Wolff, Robert A.
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Kaseb, A.
Duda, D. G.
Cao, H. S. Tran
Abugabal, Y. I.
Vence, L. M.
Rashid, A.
Pestana, R. Carmagnani
Blando, J. M.
Singh, S.
Vauthey, J. N.
Chun, Y. S.
Tzeng, C-W. D.
Sakamuri, D.
Wolff, R. A.
Yao, J. C.
Allison, J.
Sharma, P.
ANNALS OF ONCOLOGY, 2019, 30 : 880 - 880
[4] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC
Omar Kaseb, Ahmed
Duda, Dan G.
Tran Cao, Hop Sanderson
Abugabal, Yehia I.
Vence, Luis M.
Rashid, Asif
Pestana, Roberto
Blando, Jorge M.
Singh, Shalini
Vauthey, Jean-Nicolas
Hassan, Manal
Amin, Hesham M.
Qayyum, Aliya
Shin Chun, Yun
David Tzeng, Ching-Wei
Sakamuri, Divya
Wolff, Robert A.
Yao, James C.
Patrick Allison, James
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[5] Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Cao, Hop Sanderson Tran
Mohamed, Yehia, I
Qayyum, Aliya
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Lee, Sunyoung S.
Raghav, Kanwal Pratap Singh
Altameemi, Lina
Rashid, Asif
Vauthey, Jean-Nicolas
Carter, Kristen
Tzeng, Ching-Wei David
Chun, Yun Shin
Yao, James C.
Wolff, Robert A.
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] 009 Randomized, open -label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Kaseb, A.
Vence, L.
Blonde, J.
Yadav, S.
Pestana, R.
Vauthey, J.
Cao, H.
Chun, Y.
Sakamura, D.
Wolff, R.
Yoe, J.
Allison, J.
Sharma, P.
ANNALS OF ONCOLOGY, 2019, 30
[7] Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
Kaseb, Ahmed Omar
Hasanov, Elshad
Cao, Hop Sanderson Tran
Xiao, Lianchun
Vauthey, Jean-Nicolas
Lee, Sunyoung S.
Yavuz, Betul Gok
Mohamed, Yehia, I
Qayyum, Aliya
Jindai, Sonali
Duan, Fei
Basu, Sreyashi
Yadav, Shafini S.
Nicholas, Courtney
Sun, Jing Jing
Raghav, Kanwat Pratap Singh
Rashid, Asif
Carter, Kristen
Chun, Yun Shin
Tzeng, Ching-Wei David
Sakamuri, Divya
Xu, Li
Sun, Ryan
Cristini, Vittorio
Beretta, Laura
Yao, James C.
Wolff, Robert A.
Allison, James Patrick
Sharma, Padmanee
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 208 - 218
[8] A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC -X Trial).
Gonzalez, Maria
Hong, Angela M.
Carlino, Matteo S.
Atkinson, Victoria
Wang, Wei
Lo, Serigne
Brown, Michael Paul
Foote, Matthew C.
Pinkham, Mark B.
Le, Hien
Roos, Daniel E.
Osorio, Monica
Haghighi, Neda
Kok, David
Postow, Michael A.
McArthur, Grant A.
Menzies, Alexander M.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
Shah, Manish A.
Cunningham, David
Metges, Jean-Philippe
Van Cutsem, Eric
Wainberg, Zev
Elboudwarej, Emon
Lin, Kai-Wen
Turner, Scott
Zavodovskaya, Marianna
Inzunza, David
Liu, Jinfeng
Patterson, Scott D.
Zhou, Jingzhu
He, Jing
Thai, Dung
Bhargava, Pankaj
Brachmann, Carrie Baker
Cantenacci, Daniel V. T.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (12)
[10] Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Schenker, Michael
Burotto, Mauricio
Richardet, Martin
Ciuleanu, Tudor-Eliade
Goncalves, Anthony
Steeghs, Neeltje
Schoffski, Patrick
Ascierto, Paolo A.
Maio, Michele
Lugowska, Iwona
Lupinacci, Lorena
Leary, Alexandra
Delord, Jean-Pierre
Grasselli, Julieta
Tan, David S. P.
Friedmann, Jennifer
Vuky, Jacqueline
Tschaika, Marina
Konduru, Somasekhar
Vemula, Sai Vikram
Slepetis, Ruta
Kollia, Georgia
Pacius, Misena
Duong, Quyen
Huang, Ning
Doshi, Parul
Baden, Jonathan
Di Nicola, Massimo
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 11

← 1 2 3 4 5 →